EUCTR2012-002318-37-ESActive, not recruitingPhase 1
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes - The RELIEF Study
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Incyte Corporation
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •? Men or women aged ? 18 years with a confirmed diagnosis of PV according to the revised World Health Organization criteria.
- •? Subjects must currently be reporting symptoms on a stable dose of HU monotherapy and be eligible to continue HU on study after randomization. Before screening, the subject must have been receiving HU for at least 12 weeks and on the same dose for the last 4 weeks.
- •? Subjects must have completed the modified MPN-SAF screening symptom form and have a screening total symptom score (TSS) of ? 8 for the cytokine-related symptoms, or symptom cluster C (TSS-C): tiredness, itching, muscle aches, night sweats, and sweats while awake.
- •? Subjects should meet at least one of the following criteria with respect to phlebotomy and splenomegaly:
- •? No more than 1 phlebotomy within the 6 months before screening OR
- •? No palpable splenomegaly
- •? Subjects must have a hematocrit that can be controlled within 35% to 48% (inclusive) before randomization. (A phlebotomy may be performed during the screening phase to achieve this target range.)
- •? Subjects must have recovered from all side effects associated with phlebotomy, and at least 1 week must have elapsed between the phlebotomy and the beginning of the baseline phase.
- •? Subjects with Eastern Cooperative Oncology Group performance status of 0, 1, or 2 at screening.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
Exclusion Criteria
- •? Subjects with inadequate liver or renal function at screening as demonstrated by:
- •? Encephalopathy ? Grade 2 as per Child-Pugh System
- •? Hepatocellular disease
- •? Total bilirubin > 2 × upper limit of normal (ULN), unless direct bilirubin is < 2 × ULN
- •? Alanine aminotransferase > 2.5 × ULN
- •? Modification of Diet in Renal Disease estimated glomerular filtration rate < 30 mL/min/1.73 m2 or on dialysis
- •? Subjects with platelet count < 100 × 10^9/L or an absolute neutrophil count of < 1 × 10^9/L
- •? Subjects with peripheral blood blast count of > 0% at screening.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Randomized Polycythemia Vera Symptom Study comparing the effectiveness and patient assessed effects of Ruxolitinib with Hydroxyurea in a Phase 3 trialPolycythemia VeraEUCTR2012-002318-37-GBIncyte Corporation110
Active, not recruiting
Phase 1
Randomized Polycythemia Vera Symptom Study comparing the effectiveness and patient assessed effects of Ruxolitinib with Hydroxyurea in a Phase 3 trialMedDRA version: 14.1Level: HLGTClassification code 10018865Term: Haematopoietic neoplasms (excl leukaemias and lymphomas)System Organ Class: 10005329 - Blood and lymphatic system disordersPolycythemia VeraEUCTR2012-002318-37-ITINCYTE100
Active, not recruiting
Phase 1
Randomized Polycythemia Vera Symptom Study comparing the effectiveness and patient assessed effects of Ruxolitinib with Hydroxyurea in a Phase 3 trialPolycythemia VeraEUCTR2012-002318-37-BEIncyte Corporation100
Active, not recruiting
Not Applicable
Randomized Polycythemia Vera Symptom Study comparing the effectiveness and patient assessed effects of Ruxolitinib with Hydroxyurea in a Phase 3 trialPolycythemia VeraEUCTR2012-002318-37-IEIncyte Corporation100
Completed
Phase 3
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief StudyPolycythemia VeraNCT01632904Incyte Corporation110